JILUNTAI Technoloay is dedicated to providing comprehensive solutions in nuclear medicine ，molecular imaging diagnosis and treatment, and research and development of global leading proprietary radiopharmaceuticals. With the distinctive feature of integrating pharmaceuticals and medical devices, the company drives equipment innovation through pharmaceutical innovation, developing high-precision SPECT/CT technologies. Their research pipeline covers a wide range of areas including SPECT diagnostic drugs, PET diagnostic drugs, targeted therapeutic drugs, and imaging equipment.

RabPharma is a pioneering research and development platform company that specializes in addressing hard-to-treat orthopedic conditions. Driven by the unmet medical needs in China and globally, the company is developing novel therapeutics with the potential to be “first-in-class or best-in-class”.

CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease. Its product layout includes biologics, small molecules and gene therapy solutions with effective action mechanisms. Currently, CANbridge has three approved products and four drugs under development.

JiKun Medicine is an innovation-powered drug discover and development company, focusing on developing new drugs and therapeutic approaches against organ fibrosis, inflammation and immune-system disorders and cancers. JiKun has the first tier platforms and key techniques for anti-fibrosis, anti-inflammation and anti cancer drug discovery and has established a complete research and development system spanning from target discovery to clinical development, with multiple self-innovated anti-fibrotic, immunomodulatory, and oncology drugs entering the clinical stage.

Baheal Wisart focuses on cutting-edge technologies transformation and innovative medicines R&D of the cardiovascular diseases. It possesses internationally leading technologies for the preservation, isolation, cultivation and cryopreservation of human primary cardiomyocytes. Based on State Key Laboratory of Cardiovascular Disease, Baheal Wisart is fully committed to the R&D and translation of cardiovascular diseases innovative medicines, effectively serving the national strategic needs for the prevention and treatment of cardiovascular diseases.

SicaGene is a biotech company focused on the research and development of next-generation antisense oligonucleotide (ASO) drugs.The founding team comes from leading international biotechnology companies such as BeiGene and Ionis, with extensive experience in oligonucleotide drug development, clinical trials, and regulatory affairs. Small interfering RNA (siRNA) drugs primarily target specific mRNA molecules through base complementarity, interfering with mRNA translation efficiency to influence the expression of target proteins and ultimately achieve therapeutic effects.In recent years, small nucleic acid drugs have gained significant attention in the biopharmaceutical field due to their high specificity, simplicity of design, short development cycles, and abundance of target molecules. Among these, antisense oligonucleotides (ASOs) represent the most mature technology platform, with ASO drug sales reaching approximately $3.2 billion in 2023 alone, signifying one of the key directions for the future development of small nucleic acid drugs.However, no domestic company has yet brought a product to market. Based on its professional basic research, Siheng Gene has established self-developed platforms including a high-efficiency sequence design platform, a nucleic acid combination modification platform, and an innovative delivery system, enabling efficient screening of drug targets, reducing development difficulty and costs, and achieving scalable and standardized development of oligonucleotide drugs.Currently, the company focuses on drug development for difficult-to-treat diseases such as liver diseases and other metabolic disorders, ophthalmology, and the central nervous system, with multiple compounds already in preclinical research stages. Since its establishment, the company has been honored with multiple awards, including “National High-Tech Enterprise” and “Zhongguancun High-Tech Enterprise.”

Founded in 2008, BRIOHEALTH SOLUTIONS is dedicated to independently research, development, manufacturing and promoting the world’s state-of-the-art ventricular assist devices (VADs) to enable a wider range of heart failure patients and their families to live healthy and happy lives, by continuously providing exceptional service to medical professionals and patients. With the technological accumulations in the field of total magnetically levitated VADs, CH Biomedical has developed Vinovi™, the first total magnetically levitated VAD to be approved in China, and it has established comprehensive patent portfolio, and got listed in <2021 China Annual Medical Achievements> reports. In light of the latest breakthroughs in key clinical performance of its product, BRIOHEALTH SOLUTIONS is recognized as technology innovator among international VAD community. BRIOHEALTH SOLUTIONS is committed to promoting continuous innovation in the VAD industry by forging resource collaborations on a global scale, and it is becoming a next generation leader in the global VAD industry.

ZAP Surgical specializes in radiosurgery solutions, developing dedicated surgical robots for treating tumors and lesions in the brain and neck. Through multiple innovations, they offer patients worldwide with precise, efficient, and safe stereotactic radiosurgery technologies.

Relying on the nationally renowned R&D team, Huake Pioneer is a state-of-art high-end technology company. Focusing on the research and manufacture of full circumferential spherical stereotactic radiotherapy systems, the company provides radiotherapy solutions to cancer treatment.

Based on State Key Laboratory of Cardiovascular Disease, Baheal Guoxin is committed to the R&D of breakthrough technologies and achievement transformation platform for Cardiovascular Medical Devices. With the non-invasive radiotherapy system for arrhythmia as its core breakthrough, the enterprise innovatively integrates radiotherapy with cardiac electrophysiology to transform its treatment methods from invasive surgery to precise and non-invasive therapies, to drive a technological revolution in cardiovascular diseases treatment.

Taking the“14th Five Year Plan” national key research and development project, photon counting energy spectral CT, as an opportunity, Beijing Photon Counting Technology Ltd. focuses on the development and commercialization of single source and multi-source photon counting CT systems , and is dedicated to achieving technological breakthroughs in high-end imaging equipment. It has developed the CT detector ASIC chip with full IP , and owns all technologies including key components, core algorithms, sub-system and system design.

Medis Medical, specializing in minimally invasive and precise treatment solutions, has broken through the 'bottleneck' of electromagnetic navigation system. By independently developing its algorithm, Medis Medical can continuously upgrade its electromagnetic navigation system, and achieve the fusion of electromagnetic positioning and ultrasound images. It has now developed the first-in-domestic and world leading ultrasound electromagnetic positioning puncture guiding device.

Weheal Co., Ltd. is committed to providing global users with cardiovascular health monitoring, early warning, and health management service system based on mobile internet and intelligent hardware. Wehealth Inc. has independently developed software and hardware, and has obtained multiple Chinese and global patents, With over 15,000 hospitals covered in China, it will become a leading enterprise in the field.

Cailusly develops Multi-Organ-On-a-Chip micro physiological system towards personalized precision medicine. It provides a dynamic, replicable in vitro miniaturized model of human organ system that serves as research platform for the study of disease mechanisms, biological targets, and developing targeted therapeutic drugs.

Baheal Glycomtech focuses on the research of polysaccharides, glyco-proteome, and glyco-transcriptome. It is dedicated to discovering key targets and biomarkers associated with major diseases such as malignant tumors, cardiovascular diseases, autoimmune diseases, and neurodegenerative diseases.

Prociva Therapeutics has cooperated with Ocean University of China to build the small molecule drugs and natural medicine research and development center. Based on four major technology platforms, including PROTAC degraders, molecular glue degraders, small molecule drugs design and natural medicines discovery, it has developed the molecular design and mechanism validation of innovative medicines, to accelerate the original innovative medicines transformation of State Key Laboratory for Cardiovascular Disease.